Sp808
CURRENT BARRIERS AND POTENTIAL SOLUTIONS TO ADOPTION FOR ESD IN THE WEST
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
This clinical symposium will focus on the current state of the art for advanced tissue resection techniques (specifically ESD) and strategies for achieving the goal of reimbursement. ESD and third-space endoscopy has become a mainstay in the western world over the last 5-10 years but innovation in this field has been curbed due to lack of reimbursement. Tri-society attempts at obtaining a dedicated CPT code have met numerous road blocks and have left this critical field in endoscopy stifled. For the growing number of gastroenterologists now performing ESD, a pathway to reimbursement remains the hottest topic on their minds and a thoughtful clinical symposium focused on this issue would be unique and highly attended.
This clinical symposium will focus on the current state of the art for advanced tissue resection techniques (specifically ESD) and strategies for achieving the goal of reimbursement. ESD and third-space endoscopy has become a mainstay in the western world over the last 5-10 years but innovation in this field has been curbed due to lack of reimbursement. Tri-society attempts at obtaining a dedicated CPT code have met numerous road blocks and have left this critical field in endoscopy stifled. For the growing number of gastroenterologists now performing ESD, a pathway to reimbursement remains the hottest topic on their minds and a thoughtful clinical symposium focused on this issue would be unique and highly attended.
Presenter
University of Florida
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
